A shorter list of medicine names does not automatically mean a less effective plan. In fertility care, the reason for choosing or changing a preparation matters more than the apparent complexity of the list.
An older randomized IVF/ICSI comparison evaluated highly purified menotropin and recombinant FSH as alternatives within a specified treatment setting. It found comparable ongoing-pregnancy outcomes under that study's conditions. The trial does not tell an individual patient which preparation to use, but it shows why “more named products” is not a valid general measure of treatment quality.
Ask about the rationale, not the count
The sampled Reddit discussion involved concern after Menopur was removed from a later treatment plan. That concern is understandable: a changed plan can feel like something important has been taken away. The useful next step is an explanation of what the clinician learned from the previous response and what the revised plan is intended to change.
Ask which outcome drove the decision. Was the concern about the pattern of response, a safety issue, the interpretation of the prior cycle or another patient-specific factor? A clear answer should connect the change to evidence and monitoring rather than simply describe one brand as better.
Comparisons between different people on a forum cannot resolve that reasoning. Even a comparison of two cycles in the same person cannot isolate one drug if other conditions changed.
The cited study is historical and abstract-access for this article. It is not a complete review of current IVF protocols and should not be used to overrule the treating fertility team. Its limited lesson is that alternative gonadotropin strategies have been studied, so complexity alone is not evidence of benefit.
If the explanation remains unclear, ask the prescribing clinician to clarify before making any change. Do not add a research preparation to recreate someone else's medication list.